Drugs / EsoDuo®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06430047 | Nov 2022 → Jan 2025 | gastroesophageal reflux disease | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EsoDuo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06430047 ↗ |
| Route | Oral | “QD, PO” NCT06430047 ↗ |